1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. News
  7. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Evotec : partner Celmatix achieves milestone for PCOS drug programme

01/18/2022 | 08:15am EDT

New York, NY, USA, 18 January 2022:
Evotec partner Celmatix Inc., a biotechnology company focused on ovarian biology, today announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec. The milestone was triggered by Evotec and Bayer AG advancing a drug programme, centered around a novel Celmatix-identified drug target, into hit-identification.

Worldwide, hundreds of millions of women are struggling with PCOS, the most common endocrine disorder in premenopausal women. While the underlying cause of PCOS is largely unknown, genomic studies suggest a strong genetic connection.

For further information, please follow this link to the full version of the press release from Celmatix.

Disclaimer

Evotec SE published this content on 18 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 January 2022 13:14:09 UTC.


© Publicnow 2022
All news about EVOTEC SE
05/24EVOTEC : Berenberg gives a Buy rating
MD
05/19Evotec Working With Almirall to Develop New Therapies for Skin Diseases
MT
05/19Evotec and Almirall enter into a multi-target alliance in medical dermatology
EQ
05/18Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell re..
AQ
05/18EVOTEC : Deutsche Bank maintains a Buy rating
MD
05/17TRANSCRIPT : Evotec SE, Sernova Corp. - M&A Call
CI
05/17Nasdaq-Listed Evotec and Sernova Detail Strategic Partnership For Therapy to Advance 'F..
MT
05/17Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based ..
AQ
05/17EVOTEC : RBC reaffirms its Buy rating
MD
05/17Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell re..
EQ
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Financials
Sales 2022 694 M 741 M 741 M
Net income 2022 -9,46 M -10,1 M -10,1 M
Net cash 2022 88,2 M 94,2 M 94,2 M
P/E ratio 2022 -328x
Yield 2022 -
Capitalization 4 370 M 4 666 M 4 666 M
EV / Sales 2022 6,17x
EV / Sales 2023 5,23x
Nbr of Employees 4 354
Free-Float 87,7%
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | EVT | DE0005664809 | MarketScreener
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 24,73 €
Average target price 38,74 €
Spread / Average Target 56,7%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Iris Löw-Friedrich Chairman-Supervisory Board
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
EVOTEC SE-41.81%4 666
MODERNA, INC.-48.48%52 047
LONZA GROUP AG-28.07%42 228
IQVIA HOLDINGS INC.-27.93%38 488
SEAGEN INC.-11.73%25 121
ICON PUBLIC LIMITED COMPANY-31.56%17 232